Viridian Therapeutics/$VRDN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Ticker

$VRDN
Primary listing

Industry

Biotechnology

Employees

143

VRDN Metrics

BasicAdvanced
$1.4B
-
-$3.33
0.45
-

What the Analysts think about VRDN

Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.

Bulls say / Bears say

Viridian Therapeutics' lead drug candidate, veligrotug (formerly VRDN-001), demonstrated promising efficacy and safety in treating thyroid eye disease (TED), with potential to become the preferred intravenous treatment option upon commercial availability. (businesswire.com)
The company initiated pivotal development for VRDN-003, a subcutaneous autoinjector form of veligrotug, aiming to capture a significant share of the TED market with this innovative treatment option. (businesswire.com)
Viridian completed a public offering in September 2024, raising approximately $225 million, bolstering its financial position to fund ongoing clinical development and potential commercialization efforts. (businesswire.com)
Viridian reported a net loss of $76.7 million for the third quarter ended September 30, 2024, compared to a net loss of $47.7 million for the same period last year, indicating increasing operational expenses. (businesswire.com)
The company's revenue for the quarter ended September 2024 was $0.09 million, surpassing estimates but highlighting the early-stage nature of its product pipeline with minimal current revenue generation. (nasdaq.com)
Viridian's stock has experienced significant volatility, with a year-to-date decline of nearly 25% as of March 2025, reflecting investor concerns over financial performance and market competition. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

VRDN Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VRDN Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VRDN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs